^
    almost3years
    Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=104, Recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    SC10914
    over3years
    A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients (clinicaltrials.gov)
    P2, N=78, Recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd.
    Clinical • New P2 trial • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • PGR positive
    |
    SC10914
    over3years
    Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=104, Not yet recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd.
    Clinical • New P2 trial • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    SC10914
    almost4years
    SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation (clinicaltrials.gov)
    P1/2, N=90, Not yet recruiting, Jiangxi Qingfeng Pharmaceutical Co. Ltd.
    Clinical • New P1/2 trial • BRCA Biomarker • PARP Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    SC10914
    4years
    [VIRTUAL] Phase I study to assess the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary efficacy of SC10914 in patients with advanced solid tumors. (ASCO 2020)
    SC10914 has a similar structure with olaparib. SC10914 was safe in patients with advanced solid tumors. The main toxicity was blood-related adverse reactions. SC10914 was effective in gBRCAm ovarian cancer patients.
    Clinical • P1 data • PK/PD data
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    Lynparza (olaparib) • SC10914